SCHEMBL5718103

SCHEMBL5718103

COP(=O)(Cc1ccc(C#N)cc1)OC

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.48
LOXL2 Q9Y4K0 2/20 0.46
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
CYP11B1 P15538 4/20 0.40
CYP11B2 P19099 4/20 0.40
ALDH1A1 P00352 1/20 0.39
RAB9A P51151 1/20 0.39
CYP19A1 P11511 2/20 0.38
GLA P06280 1/20 0.38
MAPT P10636 2/20 0.38
POLB P06746 1/20 0.38
EPHX2 P34913 1/20 0.38
SAE1 Q9UBE0 1/20 0.38
UBA2 Q9UBT2 1/20 0.38
HTT P42858 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7891127 0.86 CYP2A6 (0.46) CYP2A6LOXL2MAOAMAOBCYP11B1
SCHEMBL2037665 0.84 KLK8 (0.36) POLB
SCHEMBL578310 0.82 CYP2A6 (0.50) CYP2A6LOXL2MAOAMAOBCYP11B1
SCHEMBL10924475 0.80 CYP2A6 (0.47) CYP2A6LOXL2MAOAMAOBCYP11B1
SCHEMBL5041135 0.80 GLA (0.63) MAOBCYP11B1CYP11B2ALDH1A1CYP19A1
SCHEMBL7043203 0.78 PTK2 (0.39) MAOBALDH1A1RAB9AMAPT
SCHEMBL8958940 0.76 AGXT (0.40) CYP2A6RAB9AMAPTTSHR
SCHEMBL13624524 0.76 SMN1; SMN2 (0.44) CYP2A6ALDH1A1RAB9AMAPTPOLB
SCHEMBL10397175 0.76 CYP2A6 (0.55) CYP2A6LOXL2CYP11B1CYP11B2ALDH1A1
SCHEMBL9803879 0.75 LOXL2 (0.38) CYP2A6LOXL2MAOBCYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230391731-A1 PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF LIANGJIANG MEDICINE CO., LTD. (CN) 2023-12-07 US disclosed
EP-1210476-B1 MIXTURES OF FLUORESCENT WHITENING AGENTS CIBA SC HOLDING AG (CH) 2006-06-14 EP disclosed
US-6719922-B1 ISOMERS OF CYANO-SUBSTITUTED 1,4-BIS-STYRYLBENZENES; SYNTHETIC POLYESTER FIBERS CIBA SPECIALTY CHEMICALS CORPORATION 2004-04-13 US disclosed
EP-1210476-A1 MIXTURES OF FLUORESCENT WHITENING AGENTS Ciba SC Holding AG (CH) 2002-06-05 EP disclosed
EP-1153011-A1 BIS-STYRYLBIPHENYL COMPOUNDS Ciba SC Holding AG (CH) 2001-11-14 EP disclosed
WO-2001018301-A1 MIXTURES OF FLUORESCENT WHITENING AGENTS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2001-03-15 WO disclosed
WO-2000047550-A1 BIS-STYRYLBIPHENYL COMPOUNDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2000-08-17 WO disclosed
EP-0238446-B1 Mixtures of optical brighteners CIBA GEIGY AG (CH) 1995-11-15 EP disclosed
US-4891153-A Mixtures of fluorescent whitening agents CIBA-GEIGY CORPORATION (US) 1990-01-02 US disclosed
US-4778622-A Mixtures of fluorescent whitening agents CIBA-GEIGY CORPORATION (US) 1988-10-18 US disclosed
EP-0238446-A1 Mixtures of optical brighteners CIBA-GEIGY AG (CH) 1987-09-23 EP disclosed
US-4016195-A OPTICAL BRIGHTENERS HOECHST AKTIENGESELLSCHAFT (DT) 1977-04-05 US disclosed
US-3957846-A OPTICAL BRIGHTENERS, LACQUERS, SYNTHETIC FIBERS HOECHST AKTIENGESELLSCHAFT (DT) 1976-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391731-A1 PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF GRPR, SLC2A8, HPGDS CYP2A6 1251/4885LOXL2 1669/4885MAOA 2559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.